The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance.
A dramatic rise in the frequency of resistance to adamantane drugs by influenza A (H3N2) viruses has occurred in recent years -- from approximately 2% to approximately 90% in multiple countries worldwide-and associated with a single S31N amino acid replacement in the viral matrix M2 protein. To explore the emergence and spread of these adamantane resistant viruses we performed a phylogenetic analysis of recently sampled complete A/H3N2 genome sequences. Strikingly, all adamantane resistant viruses belonged to a single lineage (the "N-lineage") characterized by 17 amino acid replacements across the viral genome. Further, our analysis revealed that the genesis of the N-lineage was due to a 4+4 segment reassortment event involving 2 distinct lineages of influenza A/H3N2 virus. A subsequent study of hemagglutinin HA1 sequences suggested that the N-lineage was circulating widely in Asia during 2005, and then dominated the Northern hemisphere 2005-2006 season in Japan and the USA. Given the infrequent use of adamantane drugs in many countries, as well as the decades of use in the US associated with little drug resistance, we propose that the globally increasing frequency of adamantane resistance is more likely attributable to its interaction with fitness-enhancing mutations at other genomic sites rather than to direct drug selection pressure. This implies that adamantanes may not be useful for treatment and prophylaxis against influenza viruses in the long term. More generally, these findings illustrate that drug selection pressure is not the sole factor determining the evolution and maintenance of drug resistance in human pathogens.
Simonsen
Lone
L
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Viboud
Cécile
C
Grenfell
Bryan T
BT
Dushoff
Jonathan
J
Jennings
Lance
L
Smit
Marita
M
Macken
Catherine
C
Hata
Mami
M
Gog
Julia
J
Miller
Mark A
MA
Holmes
Edward C
EC
D000218:Adamantane / Q000494:pharmacology*; D019943:Amino Acid Substitution; D000998:Antiviral Agents / Q000494:pharmacology*; D001208:Asia / Q000453:epidemiology; D001315:Australia / Q000453:epidemiology; D001681:Biological Assay; D024882:Drug Resistance, Viral / Q000235:genetics*; D019143:Evolution, Molecular; D014644:Genetic Variation; D016679:Genome, Viral; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000187:drug effects* / Q000235:genetics; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D007564:Japan / Q000453:epidemiology; D009520:New Zealand / Q000453:epidemiology; D010802:Phylogeny; D014481:United States / Q000453:epidemiology; D014763:Viral Matrix Proteins / Q000235:genetics; D000086082:Viroporin Proteins
D000218:Adamantane; D000998:Antiviral Agents; D014763:Viral Matrix Proteins; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins